Abstract
IntroductionPatients with breast cancer with homologous recombination deficiency (HRD) such as germline BRCA1/2 mutations would respond to DNA-damaging drugs. Several clinical studies have revealed that HRD biomarkers were associated with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have